title: Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
abstract: JE-CV (IMOJEV®, Sanofi Pasteur, France) is a live attenuated virus vaccine constructed by inserting coding sequences of the prM and E structural proteins of the Japanese encephalitis SA14-14-2 virus into the genome of yellow fever 17D virus. Primary immunization with JE-CV requires a single dose of the vaccine. This article reviews clinical trials of JE-CV in children aged up to 6 years conducted in countries across South-East Asia. Strong and persistent antibody responses were observed after single primary and booster doses, with 97% of children seroprotected up to five years after booster vaccination. Models of long-term antibody persistence predict a median duration of protection of approximately 30 years after a booster dose. The safety and reactogenicity profiles of JE-CV primary and booster doses are comparable to other widely used childhood vaccines.
authors.affiliation: a Department of Pediatrics, Faculty of Medicine Siriraj Hospital , Mahidol University , Bangkok , Thailand.
authors.forename: K
authors.initials: K
authors.lastname: Chokephaibulkit
authors.affiliation: b Global Medical Affairs , Sanofi Pasteur , Lyon , France.
authors.forename: G
authors.initials: G
authors.lastname: Houillon
authors.affiliation: c Clinical Development , Sanofi Pasteur , Lyon , France.
authors.forename: E
authors.initials: E
authors.lastname: Feroldi
authors.affiliation: d Asia Regional Medical Affairs and Clinical Development , Sanofi Pasteur , Singapore.
authors.forename: A
authors.initials: A
authors.lastname: Bouckenooghe
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D001210:Asia, Southeastern; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004672:Encephalitis, Japanese / Q000517:prevention & control*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D022321:Japanese Encephalitis Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000235:genetics; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics; D022341:Yellow Fever Vaccine / Q000235:genetics
chemical_list: D000914:Antibodies, Viral; D022321:Japanese Encephalitis Vaccines; D008562:Membrane Glycoproteins; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D022341:Yellow Fever Vaccine; C080628:glycoprotein E, Japanese encephalitis virus; C074932:prM protein, Flavivirus
keywords: IMOJEV®; Japanese encephalitis; flaviviridae; pediatrics; vaccines